November 30, 2017 07:13 AM EST

Sanofi’s dengue vaccine slams into a safety issue, triggering a $120M write-off and eviscerating old blockbuster projections

Sanofi spent $1.5 billion over about 20 long years to develop its dengue vaccine, believing that it had a blockbuster product headed to a massive …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi’s dengue vac­cine slams in­to a safe­ty is­sue, trig­ger­ing a $120M write-off and evis­cer­at­ing old block­buster pro­jec­tions